

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A cell line which expresses on the cell surface TF, MUC1 and glycoporphin.
2. (Cancelled)
3. (Currently amended) The cell line of claim 1 [[er-2]] which is selected from the group consisting of
 - (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606;
 - (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and
 - (c) subclones of (a) or (b).
4. (Cancelled)
5. (Currently amended) The cell line of claim 4, wherein said vector claim 1, comprising a vector which comprises a nucleic acid molecule.
6. (Original) The cell line of claim 5, wherein said nucleic acid molecule encodes at least one polypeptide of a polypeptide selected from the group consisting of a cytokine, MHC class I molecule, MHC class II molecule and costimulatory molecule, T cell epitope or multimers thereof, tumour antigen, hormone, sexual

hormone, adjuvant, antibody or other molecules or fragments thereof having biological activity or any combination thereof.

7. (Currently amended) A lysate, a molecule, or a mixture of molecules obtained from [[ef]] the cell line of any one of claims 1 to 6 claim 1.
8. (Cancelled)
9. (Currently amended) Dendritic cells loaded with the lysate, [[a]] the molecule, or [[a]] the mixture of molecules of claim 8 claim 7.
10. (Currently amended) Dendritic cells co-incubated or fused with the cells of any one of the claims 1 to 6 claim 1.
11. (Currently amended) A composition comprising the cell line of any one of claims 1 to 6, the lysate of claim 7, the molecule or mixture of molecules of claim 8, or the dendritic cells of claim 9 or 10
 - (a) a cell line which expresses on the cell surface TF, MUC1, and glycophorin;
 - (b) a lysate, a molecule, or a mixture of molecules obtained from the cell line of (a);
 - (c) dendritic cells loaded with the lysate, the molecule, or the mixture of molecules of (b); or
 - (d) dendritic cells co-incubated or fused with the cells of (a).
12. (Currently amended) The composition of claim 11, which is a pharmaceutical or vaccine composition.

13-19.(Cancelled)

20. (Currently amended) A method for the treatment or prevention of cancers and/or tumourous diseases comprising administering a therapeutically or prophylactically effective amount of the effective amount of ~~the cell line of any one of claims 1 to 6 and/or the lysate of claim 7 or a molecule or a mixture of molecules of claim 6 and/or the dendritic cells of any one of claims 9, 10, 16 or 17, the pharmaceutical composition or vaccine composition of any one of claims 12 to 15 or the dendritic cells of claim 9, 10, 16 or 17~~

(a) a cell line which expresses on the cell surface TF, MUC1, and glycophorin;

(b) a lysate, a molecule, or a mixture of molecules obtained from the cell line of (a);

(c) dendritic cells loaded with the lysate, the molecule, or the mixture of molecules of (b);

(d) dendritic cells co-incubated or fused with the cells of (a); or

(e) the pharmaceutical or vaccine composition of claim 12.

21. (Cancelled)

22. (Currently amended) The method of claim 20 ~~or the use of claim 21~~, wherein said cancer or tumourous disease is a cancer of the head and neck, lung, mediastinum, gastrointestinal tract, genitourinary system, gynaecological system, breast, endocrine system, skin, childhood, unknown primary site or metastatic cancer, a sarcoma of the soft tissue and bone, a mesothelioma, a melanoma, a

neoplasm of the central nervous system, a lymphoma, a leukaemia, a paraneoplastic syndrome, a peritoneal carcinomatosis, a immunosuppression-related malignancy and/or metastatic cancer.